Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Protagonist Therapeutics (PTGX) over the last 5 years, with Q3 2025 value amounting to -$0.62.
- Protagonist Therapeutics' EPS (Weighted Average and Diluted) fell 1481.48% to -$0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.65, marking a year-over-year decrease of 7627.74%. This contributed to the annual value of $4.23 for FY2024, which is 40421.62% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' EPS (Weighted Average and Diluted) is -$0.62, which was down 1481.48% from -$0.55 recorded in Q2 2025.
- Protagonist Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $3.26 during Q1 2024, with a 5-year trough of -$0.84 in Q2 2022.
- Over the past 5 years, Protagonist Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.58 (recorded in 2023), while the average stood at -$0.2.
- In the last 5 years, Protagonist Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 58656.72% in 2024 and then crashed by 10582.82% in 2025.
- Protagonist Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.77 in 2021, then increased by 9.09% to -$0.7 in 2022, then skyrocketed by 174.29% to $0.52 in 2023, then skyrocketed by 289.1% to $2.02 in 2024, then crashed by 130.64% to -$0.62 in 2025.
- Its last three reported values are -$0.62 in Q3 2025, -$0.55 for Q2 2025, and -$0.19 during Q1 2025.